 AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR VEGFR2. This study will assess the safety, pharmacokinetic PKpharmacodynamic PD profiles and clinical activity of AEE788 in advanced cancers. 